12/14/2007

An FDA advisory panel voted 10-2 to reject Merck & Co.'s third bid to obtain approval for an over-the-counter version of Mevacor. The panel was concerned that patients would not know how to use the cholesterol-lowering drug, which is now only available by prescription.

Related Summaries